Clinical trial
High-Density Lipoprotein (HDL) Modulation and Endothelial Function
NCT00150722 · University of Calgary, Other · Completed
Key facts
| NCT number | NCT00150722 |
|---|---|
| Title | High-Density Lipoprotein (HDL) Modulation and Endothelial Function |
| Official title | HDL Modulation and Endothelial Function |
| Lead sponsor | University of Calgary, Other |
| Collaborators | Heart and Stroke Foundation of Ontario |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atherosclerosis |
| Intervention type | Drug |
| Interventions | atorvastatin (or other tolerated statin + Niaspan/placebo) |
| Enrollment | 75 |
| Start date | Sep 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Sep 8, 2005 |
| Last update posted | Nov 10, 2008 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: